Establishment Labs Holdings Inc. filed its quarterly report on Form 10-Q with the SEC on November 6, 2026, covering the fiscal quarter ended September 30, 2026.

Key Highlights

  • Shares outstanding: 29,823,470 common shares were outstanding as of November 5, 2026, according to the filing.
  • Filer classification: The company is designated as a large accelerated filer under Rule 12b-2 of the Exchange Act.
  • Exchange listing: Common Shares, No Par Value, trade under the symbol ESTA on the Nasdaq Capital Market (NASDAQ:ESTA).
  • Incorporation jurisdiction: Establishment Labs Holdings Inc. is incorporated in the British Virgin Islands, with principal executive offices in Austin, Texas.
  • Profitability risk noted: The company disclosed that it "has incurred losses to date" and that its ability to achieve and maintain profitability depends on the commercial success of its Motiva Implants.
  • Liquidity contingency: The filing states that if available cash resources and anticipated cash flow from operations are insufficient, the company "may seek to sell equity or convertible debt securities, enter into a credit facility or another form of third-party funding, or seek other debt financing."

Establishment Labs Q3 2026 Filing: Key Disclosures on Operations and Risk Factors

Establishment Labs Holdings Inc. (NASDAQ:ESTA) submitted its Form 10-Q for the quarterly period ended September 30, 2026, filed November 6, 2026. The filing covers the company's condensed consolidated financial statements for the three and nine months ended September 30, 2026, along with management's discussion and analysis and disclosures on market risk and internal controls.

According to the filing, the company's registered common shares carry no par value and are listed on the Nasdaq Capital Market. The share count of 29,823,470, reported as of November 5, 2026, represents the most current figure disclosed in this filing. The company confirmed it is not a shell company and is not an emerging growth company.

The filing includes a forward-looking statements notice citing Section 27A of the Securities Act of 1933 and Section 21E of the Exchange Act, with the company claiming safe harbor protection under the Private Securities Litigation Reform Act of 1995. Among the risk factors disclosed, the company highlighted exposure to unfavorable global economic conditions, reliance on a single-source supplier for a key raw material, dependence on its direct sales force, and regulatory compliance obligations across multiple jurisdictions. The company also noted that its results of operations have been, and could in the future be, affected by currency rate fluctuations. These characterizations are the company's own and are subject to its cautionary language.

What Was Disclosed

Establishment Labs filed its Q3 2026 quarterly report covering the period ended September 30, 2026, disclosing 29,823,470 shares outstanding as of November 5, 2026, its large accelerated filer status, and a range of forward-looking risk factors tied to its Motiva Implants business and liquidity position.